Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Diffuse Large B-Cell Lymphoma | Research

Eukaryotic initiation factor 3a promotes the development of diffuse large B-cell lymphoma through regulating cell proliferation

Authors: Hongkun Sun, Juanjuan Shang, Xiao Liu, Shuai Ren, Shunfeng Hu, Xin Wang

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

Background

One-third of diffuse large B-cell lymphoma (DLBCL) patients suffer relapse after standard treatment. Eukaryotic initiation factor 3a (eIF3a) is a key player in the initial stage of translation, which has been widely reported to be correlated with tumorigenesis and therapeutic response. This study aimed to explore the biological role of eIF3a, evaluate its prognostic and therapeutic potential in DLBCL.

Methods

RNA-seq datasets from GEO database were utilized to detect the expression and prognostic role of eIF3a in DLBCL patients. Protein level of eIF3a was estimated by western blot and immunohistochemical. Next, DLBCL cells were transfected with lentiviral vector either eIF3a-knockdown or empty to assess the biological role of eIF3a. Then, samples were divided into 2 clusters based on eIF3a expression and differentially expressed genes (DEGs) were identified. Function enrichment and mutation analysis of DEGs were employed to detect potential biological roles. Moreover, we also applied pan-cancer and chemosensitivity analysis for deep exploration.

Results

eIF3a expression was found to be higher in DLBCL than healthy controls, which was associated with worse prognosis. The expression of eIF3a protein was significantly increased in DLBCL cell lines compared with peripheral blood mononuclear cells (PBMCs) from healthy donors. eIF3a knockdown inhibited the proliferation of DLBCL cells and the expression of proliferation-related proteins and increase cell apoptosis rate. Besides, 114 DEGs were identified which had a close linkage to cell cycle and tumor immune. eIF3a and DEGs mutations were found to be correlated to chemosensitivity and vital signal pathways. Pan-cancer analysis demonstrated that high eIF3a expression was associated with worse prognosis in several tumors. Moreover, eIF3a expression was found to be related to chemosensitivity of several anti-tumor drugs in DLBCL, including Vincristine and Wee1 inhibitor.

Conclusions

We firstly revealed the high expression and prognostic role of eIF3a in DLBCL, and eIF3a might promote the development of DLBCL through regulating cell proliferation and apoptosis. eIF3a expression was related to immune profile and chemosensitivity in DLBCL. These results suggest that eIF3a could serve as a potential prognostic biomarker and therapeutic target in DLBCL.
Appendix
Available only for authorised users
Literature
1.
Oldenburg J, Aparicio J, Beyer J, et al. Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancer. Ann Oncol. 2015;26:833–8.PubMedCrossRef
2.
Keenan M, Diamond A, Boughan K, et al. Diffuse large B cell lymphoma in patients 80 years and older: worse survival after treatment without increased relapse rates. Clin Lymphoma Myeloma Leuk. 2021;21:799–804.PubMedCrossRef
3.
Papageorgiou SG, Thomopoulos TP, Liaskas A et al. Monoclonal antibodies in the treatment of diffuse large B-Cell lymphoma: moving beyond Rituximab. Cancers (Basel) 2022;14.
4.
Chihara D, Johnston K, Bolatova T, et al. An Epidemiological Model to Estimate the prevalence of diffuse large B-Cell lymphoma in the United States. Clin Lymphoma Myeloma Leuk. 2022;22:e1092–9.PubMedCrossRef
5.
Harris LJ, Patel K, Martin M. Novel therapies for relapsed or refractory diffuse large B-Cell lymphoma. Int J Mol Sci 2020;21.
6.
Yang J, Li Y, Zhang Y, et al. Sirt6 promotes tumorigenesis and drug resistance of diffuse large B-cell lymphoma by mediating PI3K/Akt signaling. J Exp Clin Cancer Res. 2020;39:142.PubMedPubMedCentralCrossRef
7.
Schramm F, Borst A, Linne U, et al. Elucidation of the Translation Initiation Factor Interaction Network of Haloferax volcanii reveals coupling of transcription and translation in Haloarchaea. Front Microbiol. 2021;12:742806.PubMedPubMedCentralCrossRef
8.
Dong Z, Zhang JT. Initiation factor eIF3 and regulation of mRNA translation, cell growth, and cancer. Crit Rev Oncol Hematol. 2006;59:169–80.PubMedCrossRef
9.
Wolf DA, Lin Y, Duan H, et al. eIF-Three to Tango: emerging functions of translation initiation factor eIF3 in protein synthesis and disease. J Mol Cell Biol. 2020;12:403–9.PubMedPubMedCentralCrossRef
10.
11.
Spilka R, Ernst C, Bergler H, et al. eIF3a is over-expressed in urinary bladder cancer and influences its phenotype independent of translation initiation. Cell Oncol (Dordr). 2014;37:253–67.PubMedCrossRef
12.
Miao B, Wei C, Qiao Z, et al. eIF3a mediates HIF1alpha-dependent glycolytic metabolism in hepatocellular carcinoma cells through translational regulation. Am J Cancer Res. 2019;9:1079–90.PubMedPubMedCentral
13.
Liu K, Lei Z, Yao H, et al. Impact of a eukaryotic translation initiation factor 3a polymorphism on susceptibility to gastric Cancer. Med Princ Pract. 2016;25:461–5.PubMedPubMedCentralCrossRef
14.
Chen G, Burger MM. p150 overexpression in gastric carcinoma: the association with p53, apoptosis and cell proliferation. Int J Cancer. 2004;112:393–8.PubMedCrossRef
15.
Dong Z, Liu Z, Cui P, et al. Role of eIF3a in regulating cell cycle progression. Exp Cell Res. 2009;315:1889–94.PubMedCrossRef
16.
Zheng X, Wang S, Hong S, et al. Knockdown of eIF3a attenuated cell growth in K1 human thyroid cancer cells. Genes Genomics. 2021;43:379–88.PubMedCrossRef
17.
Mei C, Liu C, Gao Y, et al. eIF3a regulates colorectal Cancer Metastasis via Translational activation of RhoA and Cdc42. Front Cell Dev Biol. 2022;10:794329.PubMedPubMedCentralCrossRef
18.
Chen G, Burger MM. p150 expression and its prognostic value in squamous-cell carcinoma of the esophagus. Int J Cancer. 1999;84:95–100.PubMedCrossRef
19.
Steven M, Horwitz S, Ansell, Weiyun Z, Ai, et al. T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice guidelines in Oncology. J Natl Compr Canc Netw. 2022;20:285–308.CrossRef
20.
Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms. Leukemia. 2022;36:1720–48.PubMedPubMedCentralCrossRef
21.
Han Y, Hu X, Yun X, et al. Nucleolar and spindle associated protein 1 enhances chemoresistance through DNA damage repair pathway in chronic lymphocytic leukemia by binding with RAD51. Cell Death Dis. 2021;12:1083.PubMedPubMedCentralCrossRef
22.
Hu S, Ren S, Cai Y, et al. Glycoprotein PTGDS promotes tumorigenesis of diffuse large B-cell lymphoma by MYH9-mediated regulation of wnt-beta-catenin-STAT3 signaling. Cell Death Differ. 2022;29:642–56.PubMedCrossRef
23.
Liu J, Lichtenberg T, Hoadley KA, et al. An Integrated TCGA Pan-cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Cell. 2018;173:400–16.PubMedPubMedCentralCrossRef
24.
Zhang Y, Hua X, Shi H, et al. Systematic analyses of the role of prognostic and immunological EIF3A, a reader protein, in clear cell renal cell carcinoma. Cancer Cell Int. 2021;21:680.PubMedPubMedCentralCrossRef
25.
Spilka R, Laimer K, Bachmann F, et al. Overexpression of eIF3a in squamous cell carcinoma of the oral cavity and its putative relation to Chemotherapy Response. J Oncol. 2012;2012:901956.PubMedPubMedCentralCrossRef
26.
Chen J, Liu JY, Dong ZZ, et al. The effect of eIF3a on anthracycline-based chemotherapy resistance by regulating DSB DNA repair. Biochem Pharmacol. 2021;190:114616.PubMedCrossRef
27.
Haybaeck J, O’Connor T, Spilka R, et al. Overexpression of p150, a part of the large subunit of the eukaryotic translation initiation factor 3, in colon cancer. Anticancer Res. 2010;30:1047–55.PubMed
28.
Ma S, Dong Z, Huang Y, et al. Translation initiation factor eIF3a regulates glucose metabolism and cell proliferation via promoting small GTPase Rheb synthesis and AMPK activation. J Biol Chem. 2022;298:102044.PubMedPubMedCentralCrossRef
29.
Zhang L, Pan X, Hershey JW. Individual overexpression of five subunits of human translation initiation factor eIF3 promotes malignant transformation of immortal fibroblast cells. J Biol Chem. 2007;282:5790–800.PubMedCrossRef
30.
Dong Z, Liu LH, Han B, et al. Role of eIF3 p170 in controlling synthesis of ribonucleotide reductase M2 and cell growth. Oncogene. 2004;23:3790–801.PubMedCrossRef
31.
Zhang H, Zhai X, Liu Y et al. NOP2-mediated m5C modification of c-Myc in an EIF3A-Dependent manner to reprogram glucose metabolism and promote Hepatocellular Carcinoma Progression. 2023 30:60184.
32.
Zheng J-Y, Zhu T, Zhuo W et al. eIF3a sustains non-small cell lung cancer stem cell-like properties by promoting YY1-mediated transcriptional activation of β-catenin. 2023 213:115616.
33.
Ok CY, Xu-Monette ZY, Tzankov A, et al. Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. Cancer-Am Cancer Soc. 2014;120:1818–29.
34.
Aguilera NS, Bijwaard KE, Duncan B, et al. Differential expression of cyclin D1 in mantle cell lymphoma and other non-hodgkin’s lymphomas. Am J Pathol. 1998;153:1969–76.PubMedCrossRef
35.
Icard P, Fournel L, Wu Z, et al. Interconnection between metabolism and cell cycle in Cancer. Trends Biochem Sci. 2019;44:490–501.PubMedCrossRef
36.
Baba Y, Watanabe M, Murata A, et al. LINE-1 hypomethylation, DNA copy number alterations, and CDK6 amplification in esophageal squamous cell carcinoma. Clin Cancer Res. 2014;20:1114–24.PubMedCrossRef
37.
Italiano A, Bianchini L, Gjernes E, et al. Clinical and biological significance of CDK4 amplification in well-differentiated and dedifferentiated liposarcomas. Clin Cancer Res. 2009;15:5696–703.PubMedCrossRef
38.
Yuan K, Kuang W, Chen W, et al. Discovery of novel and orally bioavailable CDK 4/6 inhibitors with high kinome selectivity, low toxicity and long-acting stability for the treatment of multiple myeloma. Eur J Med Chem. 2022;228:114024.PubMedCrossRef
39.
Lelliott EJ, Kong IY, Zethoven M, et al. CDK4/6 inhibition promotes Antitumor Immunity through the induction of T-cell memory. Cancer Discov. 2021;11:2582–601.PubMedCrossRef
40.
41.
Tanaka Y, Momose S, Tabayashi T, et al. Abemaciclib, a CDK4/6 inhibitor, exerts preclinical activity against aggressive germinal center-derived B-cell lymphomas. Cancer Sci. 2020;111:749–59.PubMedPubMedCentralCrossRef
42.
Yuan K, Wang X, Dong H, et al. Selective inhibition of CDK4/6: a safe and effective strategy for developing anticancer drugs. Acta Pharm Sin B. 2021;11:30–54.PubMedCrossRef
43.
Yu XX, Zhu MY, Wang JR, et al. LW-213 induces cell apoptosis in human cutaneous T-cell lymphomas by activating PERK-eIF2alpha-ATF4-CHOP axis. Acta Pharmacol Sin. 2021;42:290–300.PubMedCrossRef
44.
Sun YL, Jiang WQ, Luo QY, et al. A novel Bcl-2 inhibitor, BM-1197, induces apoptosis in malignant lymphoma cells through the endogenous apoptotic pathway. BMC Cancer. 2019;20:1.PubMedPubMedCentralCrossRef
45.
Vishnu WK, Abeesh P, Guruvayoorappan C. Pyrazole (1, 2-diazole) induce apoptosis in lymphoma cells by targeting BCL-2 and BCL-XL genes and mitigate murine solid tumour development by regulating cyclin-D1 and Ki-67 expression. Toxicol Appl Pharmacol. 2021;418:115491.PubMedCrossRef
46.
Latifeh Azizi, Alana R, Cowell, Vasyl V, Mykuliak, et al. Cancer associated talin point mutations disorganise cell adhesion and migration. Sci Rep. 2021;11:347.CrossRef
47.
Zhao Huang J-K, Zhou K, Wang, et al. PDLIM1 inhibits Tumor Metastasis through activating Hippo Signaling in Hepatocellular Carcinoma. Hepatology. 2020;71:1643–59.PubMedCrossRef
48.
Feng P, Li Z, Li Y, et al. Characterization of different subtypes of Immune Cell Infiltration in Glioblastoma to Aid Immunotherapy. Front Immunol. 2022;21:799509.CrossRef
49.
Meng Zhu C, Ren YC, et al. Exome array analysis identifies variants in SPOCD1 and BTN3A2 that affect risk for gastric Cancer. Gastroenterology. 2017;152:2011–21.PubMedCrossRef
50.
Paczulla AM, Rothfelder K, Raffel S, et al. Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion. Nature. 2019;572:254–9.PubMedPubMedCentralCrossRef
51.
52.
St PM, Ohashi PS. The roles of CD8(+) T cell subsets in Antitumor Immunity. Trends Cell Biol. 2020;30:695–704.CrossRef
53.
Philip M, Schietinger A. CD8(+) T cell differentiation and dysfunction in cancer. Nat Rev Immunol. 2022;22:209–23.PubMedCrossRef
54.
de Jong M, Langendonk M, Reitsma B, et al. WEE1 inhibition synergizes with CHOP chemotherapy and radiation therapy through induction of premature mitotic entry and DNA damage in diffuse large B-cell lymphoma. Ther Adv Hematol. 2020;11:153190149.
55.
Spriano F, Chung E, Gaudio E, et al. The ETS inhibitors YK-4-279 and TK-216 are Novel Antilymphoma agents. Clin Cancer Res. 2019;25:5167–76.PubMedCrossRef
Metadata
Title
Eukaryotic initiation factor 3a promotes the development of diffuse large B-cell lymphoma through regulating cell proliferation
Authors
Hongkun Sun
Juanjuan Shang
Xiao Liu
Shuai Ren
Shunfeng Hu
Xin Wang
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-024-12166-0

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue

Research

Is low-dose computed tomography for lung cancer screening conveniently accessible in China? A spatial analysis based on cross-sectional survey

Research

Correlation between socioeconomic indices and epidemiological indices of thyroid cancer from 1990 to 2019 year: a global ecologic study

Research

HAIC Combined with lenvatinib plus PD-1 versus lenvatinib Plus PD-1 in patients with high-risk advanced HCC: a real-world study

Research

The effects of short-term, progressive exercise training on disease activity in smouldering multiple myeloma and monoclonal gammopathy of undetermined significance: a single-arm pilot study

Research

Transversal approach via a bladder neck and prostate combined longitudinal incision versus standard approach of robotic-assisted radical prostatectomy for localized prostate cancer: a retrospective analysis

Research

The application of different machine learning models based on PET/CT images and EGFR in predicting brain metastasis of adenocarcinoma of the lung
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits